Fertility and Sterility
Volume 93, Issue 7 , Pages 2150-2161 , 1 May 2010

Comparison of contraceptive ring and patch for the treatment of symptomatic endometriosis

  • Paolo Vercellini, M.D.

      Affiliations

    • Istituto Ostetrico e Ginecologico Luigi Mangiagalli, Università degli Studi di Milano, Milan, Italy
    • Corresponding Author InformationReprint requests: Paolo Vercellini, M.D., Clinica Ostetrica e Ginecologica I, University of Milan, Istituto Luigi Mangiagalli–Via Commenda, 12 - 20122 Milan, Italy (TEL: +390255032331; FAX: +390250320252).
    • ,
  • Giussy Barbara, M.D.

      Affiliations

    • Istituto Ostetrico e Ginecologico Luigi Mangiagalli, Università degli Studi di Milano, Milan, Italy
    • ,
  • Edgardo Somigliana, M.D., Ph.D.

      Affiliations

    • Fondazione Ospedale Maggiore Policlinico Mangiagalli e Regina Elena, Milan, Italy
    • ,
  • Stefano Bianchi, M.D.

      Affiliations

    • Division of Obstetrics and Gynecology, Ospedale San Giuseppe-Fatebenefratelli, Milan, Italy
    • ,
  • Annalisa Abbiati, M.D.

      Affiliations

    • Istituto Ostetrico e Ginecologico Luigi Mangiagalli, Università degli Studi di Milano, Milan, Italy
    • ,
  • Luigi Fedele, M.D.

      Affiliations

    • Istituto Ostetrico e Ginecologico Luigi Mangiagalli, Università degli Studi di Milano, Milan, Italy

Received 25 November 2008 ,Revised 7 January 2009 ,Accepted 7 January 2009.

References 

  1. Bajos N, Leridon H, Goulard H, Oustry P, Job-Spira N COCON group. Contraception: from accessibility to efficiency. Hum Reprod. 2003;18:994–999
  2. Creinin MC, Meyn LA, Borgatta L, Barnhart K, Jensen J, Burke AE, et al. Multicenter comparison of the contraceptive ring and patch. Obstet Gynecol. 2008;111:267–277
  3. Urdl W, Apter D, Alperstein A, Koll P, Schönian S, Bringer J, et al. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception. Eur J Obstet Gynecol Reprod Biol. 2005;121:202–210
  4. Vercellini P, Trespidi L, De Giorgi O, Cortesi I, Parazzini F, Crosignani PG. Endometriosis and pelvic pain: relation to disease stage and localization. Fertil Steril. 1996;65:299–304
  5. Vercellini P. Endometriosis: what a pain it is. Semin Reprod Endocrinol. 1997;15:251–261
  6. Cooper KG, Grant AM, Garrat AM. The impact of using a partially randomised patient preference design when evaluating alternative managements for heavy menstrual bleeding. BJOG. 1997;104:1367–1373
  7. Henshaw RC, Naji SA, Russell IT, Templeton AA. Comparison of medical abortion with surgical vacuum aspiration: women's preferences and acceptability of treatment. BMJ. 1993;307:714–717
  8. Nicolaides K, Brizot Mde L, Patel F, Snijders R. Comparison of chorionic villus sampling and amniocentesis for fetal karyotyping at 10-13 weeks' gestation. Lancet. 1994;344:435–439
  9. Knight G, Boulton AJ, Drury J, Gamsu DS, Moses JL, Bradley C, et al. A feasibility study of the use of continuous subcutaneous insulin infusion in diabetic clinic: patients' choice of treatment. Diabet Med. 1984;1:267–272
  10. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806–808
  11. Revised American Fertility Society classification of endometriosis: 1985. Fertil Steril. 1985;43:351–352
  12. Biberoglu KO, Behrman SJ. Dosage aspects of danazol therapy in endometriosis: short-term and long-term effectiveness. Am J Obstet Gynecol. 1981;139:645–654
  13. Stewart FH, Kaunitz AM, LaGuardia KD, Karvois D, Fisher AC, Friedman AJ. Extended use of transdermal norelgestromin/ethinylestradiol: a randomized trial. Obstet Gynecol. 2005;105:1389–1396
  14. Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani PG. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. Fertil Steril. 2002;77:52–61
  15. Vercellini P, Frontino G, De Giorgi O, Pietropaolo G, Pasin R, Crosignani PG. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen. Fertil Steril. 2003;80:560–563
  16. Cheong Y, Tay P, Luk F, Gan HC, Li TC, Cooke I. Laparoscopic surgery for endometriosis: how often do we need to reoperate?. J Obstet Gynecol. 2008;28:82–85
  17. Shakiba K, Bena JF, McGill KM, Minger J, Falcone T. Surgical treatment of endometriosis: a 7-year follow up on the requirement for further surgery. Obstet Gynecol. 2008;111:1285–1292
  18. Vercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertil Steril. 2005;84:1375–1387
  19. Vercellini P, Cortesi I, Crosignani PG. Progestins for symptomatic endometriosis: a critical analysis of the evidence. Fertil Steril. 1997;68:393–401
  20. Vercellini P, Fedele L, Pietropaolo G, Frontino G, Somigliana E, Crosignani PG. Progestogens for endometriosis: forward to the past. Hum Reprod Update. 2003;9:387–396
  21. Vercellini P, Somigliana E, Viganò P, Abbiati A, Daguati R, Crosignani PG. Endometriosis: current and future medical therapies. Best Pract Res Clin Obstet Gynaecol. 2008;22:275–306
  22. Brocklehurst P. Partially randomised patient preference trials. BJOG. 1997;104:1332–1335
  23. Togerson D, Sibbald B. Understanding controlled trials: what is a patient preference trial?. BMJ. 1998;316:360
  24. Schmoor C, Olschewski M, Schumacher M. Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. Stat Med. 1996;15:263–271
  25. Brewin CR, Bradley C. Patient preferences and randomised clinical trials. BMJ. 1989;299:313–315
  26. Concato J, Shah N, Horwitz I. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Eng J Med. 2002;342:1887–1892
  27. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Eng J Med. 2008;342:1878–1886
  28. Sculpher M. The cost-effectiveness of preference-based treatment allocation: the case of hysterectomy versus endometrial resection in the treatment of menorrhagia. Health Econ. 1998;7:129–142
  29. Victor I, Fink RA. Comparing patient telephone callback rates for different hormonal birth control delivery systems. Am J Therapeutics. 2006;13:507–512
  30. Barnhart KT, Timbers K, Pretorius ES, Lin K, Shaunik A. In vivo assessment of NuvaRing placement. Contraception. 2005;72:196–199
  31. Barreiros FA, Aparecida C, Guazzelli F, De Araùjo FF, Barbosa R. Bleeding patterns of women using extended regimens of the contraceptive vaginal ring. Contraception. 2007;75:204–208
  32. Miller L, Verhoven CHJ, Hout J. Extended regimens of the contraceptive vaginal ring. Obstet Gynecol. 2005;106:473–482
  33. LaGuardia KD, Fisher AC, Bainbridge JD, LoCoco JM, Friedman AJ. Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertil Steril. 2005;83:1875–1877
  34. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 ng of ethinyl estradiol. Contraception. 2006;73:223–228
  35. Cole JA, Norman H, Doherty M, Walzer AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109:339–346
  36. Van De Heuvel MW, Van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and oral contraceptive. Contraception. 2005;72:168–174
  37. Audet MC, Moreau M, Koltun WD, Waldbaun AS, Shangold G, Fisher AC, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. A randomized controlled trial. JAMA. 2001;285:2347–2354

 P.V. has nothing to disclose. G.B. has nothing to disclose. E.S. has nothing to disclose. S.B. has nothing to disclose. A.A. has nothing to disclose. L.F. has nothing to disclose.

 Supported in part by the University of Milan School of Medicine Research Grant FIRST no. 12-01-5068118-00067.

PII: S0015-0282(09)00110-1

doi: 10.1016/j.fertnstert.2009.01.071

Fertility and Sterility
Volume 93, Issue 7 , Pages 2150-2161 , 1 May 2010

Article Tools

* Image Usage & Resolution